BeOne Medicines (ONC) Payables (2015 - 2026)

BeOne Medicines (ONC) has reported Payables for 12 consecutive years, with $470.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables rose 30.36% year-over-year to $470.3 million in Q2 2026; TTM through Jun 2026 was $470.3 million, a 30.36% increase from a year earlier, with the FY2025 full-year figure at $479.0 million, down 61.88% from the prior year.
• Payables was $470.3 million for Q2 2026 at BeOne Medicines, up from $423.5 million in the prior quarter.
• Over five years, Payables peaked at $1.3 billion in Q4 2024 and troughed at $234.4 million in Q2 2022.
• A 5-year average of $429.6 million and a median of $337.4 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables surged 298.76% in 2024 and plunged 61.88% in 2025, its largest moves.
• Over 5 years, Payables stood at $294.8 million in 2022, then gained by 6.9% to $315.1 million in 2023, then surged by 298.76% to $1.3 billion in 2024, then sank by 61.88% to $479.0 million in 2025, then dropped by 1.82% to $470.3 million in 2026.
• The last three Payables figures came in at $470.3 million (Q2 2026), $423.5 million (Q1 2026), and $479.0 million (Q4 2025), per Business Quant data.